prostate cancer	is a	malignant neoplasm of the prostate
age	is a	risk factor for prostate cancer
African ancestry	increases risk of	prostate cancer
family history	increases risk of	prostate cancer
BRCA2 mutation	increases risk of	prostate cancer
BRCA1 mutation	increases risk of	prostate cancer
Lynch syndrome	increases risk of	prostate cancer
obesity	increases risk of	aggressive prostate cancer
smoking	increases risk of	aggressive prostate cancer
diet	influences risk of	prostate cancer
physical activity	reduces risk of	prostate cancer
PSA test	is used for	prostate cancer screening
digital rectal examination	is used for	prostate cancer screening
biopsy	confirms	prostate cancer
Gleason score	assesses	cancer aggressiveness
Gleason score	guides	risk stratification
TNM stage	guides	treatment planning
MRI	evaluates	local extent of prostate cancer
CT scan	evaluates	lymph node involvement
bone scan	detects	bone metastases
PSMA PET scan	detects	metastatic disease
PSA velocity	predicts	disease progression
PSA doubling time	predicts	progression-free survival
perineural invasion	indicates	aggressive cancer
lymph node involvement	upstages	disease
biochemical recurrence	signals	cancer progression
castration-resistant prostate cancer	is a stage of	prostate cancer
metastatic prostate cancer	informs	treatment planning
localized prostate cancer	informs	treatment choice
radical prostatectomy	is a treatment for	localized prostate cancer
external beam radiotherapy	is a treatment for	localized prostate cancer
brachytherapy	is a treatment for	localized prostate cancer
watchful waiting	is a management strategy for	low-risk prostate cancer
active surveillance	is a management strategy for	low-risk prostate cancer
androgen deprivation therapy	is a treatment for	advanced prostate cancer
orchiectomy	is a treatment for	advanced prostate cancer
leuprolide	is a	LHRH agonist
degarelix	is a	GnRH antagonist
docetaxel	treats	metastatic prostate cancer
cabazitaxel	treats	metastatic castration-resistant prostate cancer
abiraterone	treats	metastatic castration-resistant prostate cancer
enzalutamide	treats	metastatic castration-resistant prostate cancer
apalutamide	treats	nonmetastatic castration-resistant prostate cancer
sipuleucel-T	treats	asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
olaparib	treats	BRCA2-mutated prostate cancer
rucaparib	treats	BRCA-mutated prostate cancer
PARP inhibitors	cause	anemia
androgen receptor signaling	drives	prostate cancer progression
PTEN loss	associates with	poor prognosis
DNA damage repair mutation	predicts sensitivity to	PARP inhibitors
AR amplification	correlates with	castration resistance
MSI-high status	predicts benefit from	immunotherapy in prostate cancer
tumor mutational burden	is low in	prostate cancer
testosterone suppression	delays	disease progression
radiation therapy	achieves	local control of cancer
surgical margins	influence	recurrence risk
positive surgical margins	correlate with	recurrence risk
neoadjuvant therapy	considered for	localized prostate cancer
adjuvant therapy	considered for	post-prostatectomy
salvage radiotherapy	used for	post-prostatectomy recurrence
nerve-sparing surgery	preserves	erectile function
pelvic lymph node dissection	provides	staging information
imaging-guided biopsy	improves	diagnostic accuracy
PSA decline	indicates	treatment response
biochemical response	indicates	treatment response
overall survival	is an outcome for	prostate cancer
progression-free survival	is an outcome for	prostate cancer
cancer-specific survival	is an outcome for	prostate cancer
quality of life	is affected by	prostate cancer treatment
bone metastases	cause	bone pain
anemia	is a side effect of	PARP inhibitors
neutropenia	is a side effect of	chemotherapy
fatigue	is a side effect of	androgen deprivation therapy
hypertension	is a side effect of	abiraterone
osteoporosis	is a complication of	androgen deprivation therapy
metabolic syndrome	is a complication of	androgen deprivation therapy
testicular atrophy	is a side effect of	androgen deprivation therapy
hot flashes	is a side effect of	androgen deprivation therapy
weight gain	is a side effect of	androgen deprivation therapy
lipid abnormalities	are side effects of	androgen deprivation therapy
radiation-induced proctitis	is a complication of	pelvic radiotherapy
rectal bleeding	is a complication of	pelvic radiotherapy
urethral stricture	is a complication of	radical prostatectomy
urinary incontinence	persists after	radical prostatectomy
erectile dysfunction	persists after	prostate cancer treatment
rectal toxicity	is a complication of	pelvic radiotherapy
radiation enteritis	is a complication of	pelvic radiotherapy
PSA monitoring	is part of	post-treatment follow-up
disease progression	signals	clinical deterioration
hospital readmission	occurs with	post-prostatectomy complications
mortality	risk is higher with	metastatic prostate cancer
recurrence	occurs after	local therapy
genetic testing	informs	targeted therapy selection
family history	prompts	genetic testing for predisposition
HRD status	informs	PARP inhibitor eligibility
economic burden	is associated with	prostate cancer treatment
bone health	requires	monitoring during androgen deprivation therapy
bone mineral density testing	monitors	osteoporosis risk during ADT
PSA monitoring	continues during	post-treatment follow-up
immunotherapy	provides	survival benefit in select metastatic patients
clinical trial	may inform	treatment choice
